Samuel P. Niles

Samuel's recent experience includes advising:

Public Offerings

• The underwriters in Aerovate Therapeutics’ US$140 million IPO of common stock
• Aziyo Biologics in its US$50 million IPO of Class A and Class B common stock
• Lyra Therapeutics in its US$60 million IPO of common stock
• Homology Medicines in its:
  • US$166 million initial public offering of common stock
  • Multiple follow-on public offerings of common stock
• The underwriters in connection with Rubius Therapeutics':
  • US$275 million IPO of common stock
  • US$200 follow-on public offering of common stock
• The underwriters in connection with Kaleido Biosciences'
  • US$75 million IPO of common stock
  • Subsequent follow-on public offerings of common stock
• The underwriters in resTORbio’s US$98 million IPO of common stock
• Ra Pharma in its US$150 million follow-on public offering of common stock
• ContraFect in its US$52 million public offering of common stock and warrants to purchase common stock and concurrent private placement of common stock and warrants to purchase common stock
• The underwriter in Collegium Pharmaceutical’s US$125 million registered public offering of senior convertible notes
• The underwriters in Blueprint Medicines’ US$345 million follow-on public offering of common stock
• The underwriter in Akebia Therapeutics' US$89 million follow-on public offering of common stock
• The underwriters in Clearside Biomedical's US$85 million follow-on public offering of common stock

Alternative Financing Transactions

• Everest Consolidator in its US$172 million SPAC IPO of units
• Aziyo Biologics in its US$14 million PIPE financing
• Lyra Therapeutics in its US$100 million PIPE financing
• Rafael Holdings in its US$104 million PIPE financing
• The sales agent in Neptune Wellness’ US$50 million ATM program of common stock under the US-Canadian multijurisdictional disclosure system
• Affiliates of Ally Bridge Group in multiple venture capital, PIPE, and other alternative investments
• Mallinckrodt on certain securities matters relating to its chapter 11 bankruptcy proceedings

Emerging Company Matters

• Indigo Agriculture in its US$535 million Series F financing and on prior investment rounds
• Dewpoint Therapeutics in its US$150 million Series C financing, and on prior investment rounds and formation and general corporate matters
• Kojin Therapeutics in its US$60 million Series A financing and on formation and general corporate matters
• KSQ Therapeutics in its US$80 million Series C financing and on in prior investment rounds and on general corporate matters
• Biothea Pharma in its Series A financing
• CIBO Technologies in its US$30 million Series C financing and on prior investment rounds and general corporate matters
• Jnana Therapeutics in its US$50 million Series B financing and on general corporate matters
• Ring Therapeutics in its US$117 million Series B financing and on general corporate matters
• Cellarity in its US$123 million Series B financing and on general corporate matters
• Atea Pharmaceuticals in its US$215 million Series D financing
• Centrexion Therapeutics in its US$67 million Series D financing and on general corporate matters
• Various other early-stage venture-backed start-up companies, in financing, securities, employment, intellectual property, and general corporate governance matters